Clinical trials · Washington, D.C., DC
Sickle Cell Disease clinical trials in Washington, D.C.
We’re tracking 39 recruiting sickle cell disease studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT06699849RecruitingPhase 2
CSL889 for sickle cell pain crisis
This trial tests a new medicine, CSL889, for people with sickle cell disease who are currently having a pain crisis (vaso-occlusive crisis). The goal is to see if it safely helps reduce the pain and speed recovery.
Washington D.C., District of ColumbiaAges 12 years+ - NCT06975865RecruitingPhase 3
Rilzabrutinib for sickle-cell disease pain episodes
This study tests an oral medicine called rilzabrutinib to see if it can reduce painful episodes in people with sickle-cell disease. It may be an option if you have regular pain crises and are looking for a new treatment.
Washington D.C., District of ColumbiaAges 10–65 - NCT00081523Recruiting
Understanding How Sickle Cell Disease Develops Over Time
This research study follows people with sickle cell disease to learn how the condition affects their health over many years. By studying patients regularly, researchers hope to better understand the disease and improve care.
Washington D.C., District of ColumbiaAges 2–90 - NCT05775224Enrolling by invitation
Join a research data hub for sickle cell or multiple myeloma
This study builds a database of people with sickle cell disease and/or active multiple myeloma (diagnosed or treated in recent years). It may help researchers learn how these illnesses behave and support better future studies or treatments.
Washington D.C., District of ColumbiaAges Any age - NCT03587272RecruitingPhase 2
Sibling bone marrow transplant to reduce treatment side effects
This study tests a way to do a bone marrow (stem cell) transplant from an HLA-matched sibling in children with sickle cell disease, aiming to lower the risk of serious side effects. You may be considered if you have certain past sickle complications and your body can safely handle the transplant plan.
Washington D.C., District of ColumbiaAges 2–25 - NCT04398628Recruiting
Study of non-cancer blood disorders in people with bleeding or clotting
This study follows people with inherited or acquired non-cancer blood disorders to better understand symptoms, causes, and how different treatments work over time. You may be placed into a disorder-specific group, depending on your diagnosis and testing results.
Washington D.C., District of ColumbiaAges Any age - NCT04657822RecruitingPhase 4
Crizanlizumab rollover study for people with sickle cell disease
This study lets people with sickle cell disease who already finished a Novartis crizanlizumab trial continue treatment under a rollover plan. It’s designed for participants who benefited from crizanlizumab and completed the earlier study schedule without major ongoing side effects.
Washington D.C., District of ColumbiaAges 6 months–100 years - NCT06770010Recruiting
Digital brain training for kids with sickle cell disease
This trial is testing a digital program to help improve working memory (the ability to hold and use information in your mind) for children with sickle cell disease. If you join, you'll use a computer-based training program at home and researchers will see if it works and is easy to use.
Washington D.C., District of ColumbiaAges 7–16 - NCT06941389Recruiting
Comparing stem cell transplant vs standard therapy for sickle cell disease
This study compares two treatment approaches for children with sickle cell anemia: a stem cell transplant from a matched family donor versus continuing regular disease-modifying medicines. It aims to see which treatment works better over time.
Washington D.C., District of ColumbiaAges 3–20 - NCT05099874Recruiting
Computer training to improve attention in sickle cell disease
This trial tests whether a computer-based “attention control” training program can improve attention and daily functioning in children with sickle cell disease. To join, you must meet certain criteria and also pass an initial attention screening test during the study.
Washington D.C., District of ColumbiaAges 8–16 - NCT06358638RecruitingPhase 2
Sickle cell transplant using a gentler approach for patients with donor antibodies
This trial is testing a new, gentler type of bone marrow transplant for children and young adults with sickle cell disease who have a healthy sibling donor with a mismatched blood type or who have antibodies against their donor's red blood cells. The goal is to replace the faulty bone marrow with healthy donor cells, with fewer side effects than traditional transplants.
Washington D.C., District of ColumbiaAges 2–25 - NCT06439082RecruitingPhase 3
Crizanlizumab for sickle cell pain crises
This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.
Washington D.C., District of ColumbiaAges 12–100 - NCT06635902RecruitingPhase 2
Citrulline for sickle cell pain crisis
This trial tests if an intravenous medication called L-citrulline can help treat pain crises in children and young adults with sickle cell disease. Participants receive either the study drug or a placebo while in the hospital for a severe pain episode.
Washington D.C., District of ColumbiaAges 4–21 - NCT06612268RecruitingPhase 3
Etavopivat for reducing sickle cell pain crises
This study tests an investigational oral pill called etavopivat that may help reduce pain crises in people with sickle cell disease. You may qualify if you have frequent pain crises and are not on regular blood transfusions.
Washington D.C., District of ColumbiaAges 12 years+ - NCT06609226RecruitingPhase 3
Long-term safety study of etavopivat for sickle cell disease or thalassaemia
This study looks at the long-term safety and benefits of taking etavopivat for people with sickle cell disease or thalassaemia who have already been helped by it in a previous trial. It aims to see if staying on the treatment continues to be safe and effective.
Washington D.C., District of ColumbiaAges 2 years+ - NCT06664541Enrolling by invitation
Gene therapy decisions and quality of life
This study looks at how people with blood diseases and their families make decisions about gene therapy, and how it affects their quality of life. It involves interviews or surveys to understand your experience.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05904093RecruitingPhase 1
Testing a new pill for sickle cell disease safety
This study tests a medication called fostamatinib to see if it is safe and tolerable for people with sickle cell disease. It may offer a new treatment option for managing the condition.
Bethesda, MarylandAges 18–65 - NCT07224360RecruitingPhase 2
Safety of a new drug for sickle cell pain
This study tests a new medicine called anumigilimab to see if it is safe for people with sickle cell disease. The study focuses on those who have had pain crises recently, to help manage and prevent them.
Bethesda, MarylandAges 18 years+ - NCT05170412Recruiting
Diet habits study for adults with sickle cell disease
This study asks adults with sickle cell disease about what they eat and their eating routines. The goal is to understand diet patterns in sickle cell and how they may relate to health, which could help future care and guidance.
Bethesda, MarylandAges 18–120 - NCT03937817Recruiting
Donate samples to study globin gene variants
This study collects common body samples to learn how different globin gene variants work and how they relate to health. Your samples may also be used later for new research, including genetic testing.
Bethesda, MarylandAges 18–70 - NCT06944067Recruiting
Genetic risk of immune response after blood transfusions in sickle cell disease
This study looks at whether certain genes make people with sickle cell disease more likely to develop an immune reaction to blood transfusions. It aims to help doctors predict transfusion risks and improve care.
Bethesda, MarylandAges 2–99 - NCT07566494RecruitingPhase 1
Testing VAS-101 for sickle cell disease
This early-phase trial tests a new drug called VAS-101 for people with sickle cell disease. It aims to find a safe dose and see how the drug affects the body.
Bethesda, MarylandAges 18–90 - NCT03685721Recruiting
Study genes in sickle cell disease to compare blood test activity
This study looks at how a person’s genes relate to certain measurements in red blood cells in people with sickle cell disease. The goal is to understand why blood cell function varies and how that might guide future care.
Bethesda, MarylandAges 18–80 - NCT04008368RecruitingPhase 1/Phase 2
Second stem cell transplant for sickle cell with declining donor cells
This Phase 1/2 study tests whether repeating a stem cell transplant can help people with sickle cell disease (SCD) whose donor cells are no longer holding strong. It may help restore healthier blood cell production and reduce symptoms such as pain crises and severe anemia.
Bethesda, MarylandAges 2–80
Hear when a new Sickle Cell Disease trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Sickle Cell Disease trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting sickle cell disease studies listed above.
- National Institutes of Health Clinical Center · 8 studies
- Children's National Hospital · 5 studies
- ASH Research Collaborative
- Center for Cancer and Blood Disorders
- Children's National Health System
- Children's National Hemophilia Center
- Children's National Hospital (MRD-HCT)
- Children's National Medical Center
What taking part in a sickle cell disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting sickle cell disease studies in District of Columbia.
Common questions
- Are there sickle cell disease clinical trials near Washington, D.C.?
- Yes. We're currently tracking 39 recruiting sickle cell disease studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a sickle cell disease study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a sickle cell disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New sickle cell disease studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.